Teachers Retirement System of The State of Kentucky Makes New Investment in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Teachers Retirement System of The State of Kentucky acquired a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 103,802 shares of the company’s stock, valued at approximately $7,090,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. US Bancorp DE lifted its stake in shares of Apellis Pharmaceuticals by 391.2% in the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock valued at $56,000 after purchasing an additional 884 shares during the period. Point72 Hong Kong Ltd acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $65,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $70,000. Coston McIsaac & Partners acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $136,000. Finally, Great West Life Assurance Co. Can lifted its stake in shares of Apellis Pharmaceuticals by 15.5% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,734 shares of the company’s stock valued at $202,000 after purchasing an additional 500 shares during the period. 87.26% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Jeffrey Eisele sold 1,646 shares of the company’s stock in a transaction that occurred on Thursday, February 23rd. The stock was sold at an average price of $68.76, for a total value of $113,178.96. Following the completion of the transaction, the insider now directly owns 53,883 shares of the company’s stock, valued at $3,704,995.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director A. Sinclair Dunlop sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $50.70, for a total value of $25,350.00. Following the transaction, the director now owns 132,797 shares in the company, valued at $6,732,807.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jeffrey Eisele sold 1,646 shares of the company’s stock in a transaction that occurred on Thursday, February 23rd. The shares were sold at an average price of $68.76, for a total value of $113,178.96. Following the completion of the transaction, the insider now owns 53,883 shares in the company, valued at approximately $3,704,995.08. The disclosure for this sale can be found here. Insiders sold a total of 83,934 shares of company stock valued at $4,497,717 over the last three months. Corporate insiders own 8.00% of the company’s stock.

Apellis Pharmaceuticals Stock Performance

Shares of APLS opened at $63.02 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.78 and a current ratio of 4.29. The stock has a 50 day moving average price of $56.99 and a two-hundred day moving average price of $55.96. The firm has a market capitalization of $7.01 billion, a P/E ratio of -10.28 and a beta of 1.19. Apellis Pharmaceuticals, Inc. has a 52 week low of $33.32 and a 52 week high of $70.75.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) last issued its quarterly earnings data on Tuesday, February 21st. The company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.45) by ($0.05). The company had revenue of $22.70 million for the quarter, compared to the consensus estimate of $24.44 million. Apellis Pharmaceuticals had a negative return on equity of 204.77% and a negative net margin of 864.70%. Apellis Pharmaceuticals’s quarterly revenue was down 62.4% on a year-over-year basis. Equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -5.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. HC Wainwright boosted their price objective on Apellis Pharmaceuticals from $75.00 to $87.00 and gave the company a “buy” rating in a research note on Tuesday, February 21st. Needham & Company LLC boosted their target price on Apellis Pharmaceuticals from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, February 21st. Robert W. Baird boosted their target price on Apellis Pharmaceuticals from $90.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 21st. Wells Fargo & Company lowered Apellis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $83.00 to $58.00 in a research report on Monday, January 2nd. Finally, Stifel Nicolaus boosted their target price on Apellis Pharmaceuticals from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday, February 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.40.

About Apellis Pharmaceuticals

(Get Rating)

Apellis Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.